Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early proactive switch to E/C/F/TAF in primary HIV-1 infection
2016-002006-39Phase 4Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Ultrasensitive HIV RNA suppression at week 48. Started Jun 2021; status: completed.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2016-002006-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002006-39.